<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432019000600005</article-id>
<article-id pub-id-type="doi">10.7399/fh.11221</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma]]></article-title>
<article-title xml:lang="es"><![CDATA[Evaluación económica y análisis de impacto presupuestario de mepolizumab en asma eosinofílica refractaria grave]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Mochón]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A1b"/>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil-Sierra]]></surname>
<given-names><![CDATA[Manuel David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alegre-del Rey]]></surname>
<given-names><![CDATA[Emilio Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alarcón-de-la-Lastra-Romero]]></surname>
<given-names><![CDATA[Catalina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Hidalgo]]></surname>
<given-names><![CDATA[Marina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A1a">
<institution><![CDATA[,Andalusian School of Public Health  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="A1b">
<institution><![CDATA[,Biomedical Research Center at Ciber for Epidemiology and Public Health (CIBERESP by its Spanish acronym)  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="A1c">
<institution><![CDATA[,Biomedical Research Institute  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="A1d">
<institution><![CDATA[,University of Granada University Hospitals of Granada ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Puerto Real University Hospital Pharmacy Service ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,University of Seville School of Pharmacy Department of Pharmacology]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>43</volume>
<numero>6</numero>
<fpage>187</fpage>
<lpage>193</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432019000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432019000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432019000600005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin E who are candidates of omalizumab and mepolizumab, as well as mepolizumab's economic impact, lead to make efficient economic studies for clinical decision making. The aim was to analyze mepolizumab's cost-efficacy and budget impact.  Method Cost comparison and the use of mepolizumab's budgetary impact was performed, from the Spanish National Health System's perspective. Among the assessed alternatives, inhaled systemic corticosteroids, plus long acting beta agonist (&#946;2) and/or oral systemic corticosteroids in patients with non immunoglobulin E-mediated severe allergic asthma, and said treatment along with omalizumab in patients with immunoglobulin E mediated eosinophilic allergic asthma were included. Its efficacy was evaluated through avoided clinically relevant exacerbations. The direct costs associated with exacerbation were assessed.  Results Mepolizumab's long run average incremental cost regarding omalizumab's is 797 euros per patient a year. Considering omalizumab's alternative discounted price, including mepolizumab for patients with immunoglobulin E mediated eosinophilic allergic asthma would increase public spending from 2.3 to 4.6 million euros. Given omalizumab's notified price, the gradual introduction of mepolizumab in the Spanish National Health System would save 3.6 million euros in three years. For non immunoglobulin E-mediated severe asthma patients, the avoided cost/exacerbation by introducing mepolizumab is 15,085 euros, assuming a gradual market penetration of mepolizumab. In patients with &#8805; 500 eosinophils/µL, this cost decreases to 7,767 euros per avoided exacerbation with a budgetary impact of 183.2 million euros in three years with a progressive penetration of mepolizumab.  Conclusions The cost comparison between mepolizumab and omalizumab in immunoglobulin E mediated eosinophilic asthma patients suggests a use of the lower cost drug, promoting price competition. Additionally, prioritizing its use among non immunoglobulin E-mediated severe refractory eosinophilic asthma patients and &#8805; 500 eosinophils/µL plasma level patients, would improve its efficiency as well as reducing its budgetary impact.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de inmunoglobulina E candidatos a omalizumab y mepolizumab, e impacto económico de mepolizumab obligan a realizar estudios económicos para tomar decisiones clínicas eficientes. El objetivo fue realizar un análisis de coste/eficacia e impacto presupuestario de mepolizumab.  Método Se realizó la comparación de costes e impacto presupuestario del uso de mepolizumab desde la perspectiva del Sistema Nacional de Salud. Las alternativas valoradas fueron corticosteroides sistémicos inhalados + agonista &#946;2 de larga duración y/o corticosteroides sistémicos orales en pacientes con asma alérgica grave no mediada por inmunoglobulina E, y este tratamiento junto a omalizumab en pacientes con asma eosinofílica alérgica mediada por inmunoglobulina E. La eficacia se evaluó mediante exacerbaciones clínicamente relevantes evitadas. Se valoraron los costes directos asociados a exacerbación.  Resultados El coste incremental medio de mepolizumab respecto a omalizumab es de 797 euros por paciente y año. Considerando precio alternativo con descuento de omalizumab, incluir mepolizumab para pacientes con asma eosinofílica alérgica y mediada por inmunoglobulina E supondría incrementar el gasto público de 2,3 a 4,6 millones de euros. Teniendo en cuenta el precio notificado de omalizumab, la introducción gradual de mepolizumab en el Sistema Nacional de Salud supondría ahorrar 3,6 millones de euros en tres años. Para pacientes con asma grave no mediada por inmunoglobulina E, el coste/exacerbación evitada al añadir mepolizumab es de 15.085 euros, con un impacto presupuestario en tres años de 578,4 millones de euros, asumiendo una penetración progresiva de mepolizumab en el mercado. En los pacientes con &#8805; 500 eosinófilos/µl, este coste disminuye a 7.767 euros por exacerbación evitada, con un impacto presupuestario de 183,2 millones de euros en tres años con penetración progresiva de mepolizumab.  Conclusiones La comparación de costes entre mepolizumab y omalizumab en pacientes con asma eosinofílica mediada por inmunoglobulina E señala como razonable utilizar el fármaco de menor coste, promoviendo competencia de precios. Asimismo, priorizar su uso en pacientes con asma eosinofílica refractaria grave no mediada por inmunoglobulina E y niveles plasmáticos &#8805; 500 eosinófilos/µl permitiría mejorar la eficiencia y disminuir el impacto presupuestario.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Costs]]></kwd>
<kwd lng="en"><![CDATA[Economic assessment]]></kwd>
<kwd lng="en"><![CDATA[Budgetary impact]]></kwd>
<kwd lng="en"><![CDATA[Mepolizumab]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
<kwd lng="es"><![CDATA[Costes]]></kwd>
<kwd lng="es"><![CDATA[Evaluación económica]]></kwd>
<kwd lng="es"><![CDATA[Impacto presupuestario]]></kwd>
<kwd lng="es"><![CDATA[Mepolizumab]]></kwd>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of bronchial hyperreactivity and asthma in young adults from 5 Spanish areas. European study of asthma]]></article-title>
<collab>Spanish Group of the European Study on Asthma</collab>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>1996</year>
<volume>106</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>761-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of Uncontrolled Severe Persistent Asthma in Pneumology and Allergy Hospital Units in Spain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quirce]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Plaza]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Picado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vennera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Casafont]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2011</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<source><![CDATA[Guía Española para el Manejo del Asma (GEMA 4.3)]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Luzan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Brozek]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sterk]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Respir J]]></source>
<year>2014</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>343-73</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha técnica Xolair® 150 mg solución inyectable]]></source>
<year></year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Centro de información de medicamentos (CIMA)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha técnica Nucala ® 100 mg polvo para solución inyectable]]></source>
<year></year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Centro de información de medicamentos (CIMA)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Nucala®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavord]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Korn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Howarth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bleecker]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Buhl]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Keene]]></surname>
<given-names><![CDATA[ON]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<numero>9842</numero>
<issue>9842</issue>
<page-range>651-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Pavord]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Brusselle]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[FitzGerald]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Chetta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1198-207</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[High blood eosinophil count is associated with more frequent asthma attacks in asthma patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Khatry]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Ke]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Gossage]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2014</year>
<volume>113</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Rigazio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Bleecker]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Corrigan]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[Informe de Posicionamiento Terapeutico de mepolizumab (Nucala®) como tratamiento adicional en el asma eosinofilica refractaria grave]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<source><![CDATA[Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients - Full Text View - ClinicalTrials.gov]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha técnica Cinqaero ® 10 mg/ml concentrado para solución para perfusion Centro de información de medicamentos (CIMA)]]></source>
<year></year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha técnica Fasenra ® 30 mg solución inyectable en jeringa precargada. Centro de información de medicamentos (CIMA)]]></source>
<year></year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Propuesta de guía para la evaluación evaluación aplicada a las tecnologías sanitarias]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez Bastida]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antonanzas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Altes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Gac Sanit]]></source>
<year>2010</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>154-70</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Budget Impact Analysis. Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Mauskopf]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Augustovski]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Caro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Km]]></surname>
<given-names><![CDATA[Lee]]></given-names>
</name>
<name>
<surname><![CDATA[Minchin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Value in Health]]></source>
<year>2014</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-14</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<collab>Instituto Nacional de Estadistica</collab>
<source><![CDATA[España en cifras 2015]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<collab>Consejo General de Colegios Oficiales de Farmaceuticos</collab>
<source><![CDATA[BOT Plus 2. Base de Datos de Medicamentos]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Consejo General de Colegios Oficiales de Farmaceuticos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Coste económico del paciente asmático en España (estudio AsmaCost)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Moragon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Serra-Batlles]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Diego]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Palop]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Casan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio-Terres]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2009</year>
<volume>45</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>481-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Getting better value from the NHS drug budget]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moon]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Flett]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Godman]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Grosso]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Wierzbicki]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2010</year>
<volume>341</volume>
<page-range>c6449</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Beasley]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ayres]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Slavin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hebert]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[INNOVATE Allergy]]></source>
<year>2005</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>309-16</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations?: Results From a Large Cohort of Patients With Severe Uncontrolled Asthma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grimaldi-Bensouda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zureik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aubier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Benichou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Chest]]></source>
<year>2013</year>
<volume>143</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>398-405</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McQueen]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Sheehan]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Whittington]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Boven]]></surname>
<given-names><![CDATA[JFM van]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[PharmacoEconomics]]></source>
<year>2018</year>
<volume>36</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>957-71</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cockle]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Stynes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gunsoy]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Parks]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso-Cristancho]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wex]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Respir Med]]></source>
<year>2017</year>
<volume>123</volume>
<page-range>140-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nachef]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mashtare]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zhuang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mador]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[J Asthma]]></source>
<year>2018</year>
<volume>55</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>89-100</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="">
<collab>Canadian Agency for Drugs and Technologies in Health (CADTH)</collab>
<source><![CDATA[CDR Clinical Review Report for Nucala®]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermejo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Harnan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clowes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacoeconomics (journal at Internet)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whittington]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[McQueen]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Ollendorf]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Tice]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2017</year>
<volume>118</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>220-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks: final report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tice]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ollendorf]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Shore]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Weissberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Institute for Clinical and Economic Review ICER]]></source>
<year>2016</year>
<page-range>1-88</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
